The novel arylamidine T-2307 demonstrates in vitro and in vivo Activity against Candida auris

Nathan P. Wiederhold, Laura K. Najvar, Rosie Jaramillo, Marcos Olivo, Hoja Patterson, April Connell, Yoshiko Fukuda, Junichi Mitsuyama, Gabriel Catano, Thomas F. Patterson

Research output: Contribution to journalArticle

Abstract

The in vitro and in vivo activity of the arylamidine T-2307 against Candida auris was evaluated. T-2307 demonstrated in vitro activity (MIC ranges ≤ 0.008 to 0.015 μg/ml at 50% inhibition; 0.125 to >4 μg/ml at 100% inhibition). Treatment with T-2307 (3 mg/kg subcutaneous [SC] once daily) also significantly improved survival (70% at 21 days postinfection) and reduced kidney fungal burden (5.06 log10 CFU/g) compared to control (0% survival and 7.09 log10 CFU/g) (P < 0.01).

Original languageEnglish (US)
Article numbere02198
JournalAntimicrobial agents and chemotherapy
Volume64
Issue number3
DOIs
StatePublished - Jan 1 2020

Keywords

  • Candida auris
  • Caspofungin
  • Fluconazole
  • In vitro susceptibility
  • Invasive candidiasis
  • Murine model
  • T-2307

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'The novel arylamidine T-2307 demonstrates in vitro and in vivo Activity against Candida auris'. Together they form a unique fingerprint.

  • Cite this

    Wiederhold, N. P., Najvar, L. K., Jaramillo, R., Olivo, M., Patterson, H., Connell, A., Fukuda, Y., Mitsuyama, J., Catano, G., & Patterson, T. F. (2020). The novel arylamidine T-2307 demonstrates in vitro and in vivo Activity against Candida auris. Antimicrobial agents and chemotherapy, 64(3), [e02198]. https://doi.org/10.1128/AAC.02198-19